S&P 500   3,384.40 (+0.64%)
DOW   27,906.44 (+0.45%)
QQQ   280.85 (+1.08%)
AAPL   116.62 (+0.70%)
MSFT   212.16 (+0.87%)
FB   266.04 (+1.58%)
GOOGL   1,485.87 (+1.38%)
AMZN   3,189.69 (+1.30%)
TSLA   438.98 (+2.32%)
NVDA   541.52 (+0.06%)
BABA   291.17 (-0.96%)
CGC   14.23 (-0.63%)
MU   47.56 (+1.28%)
GE   6.17 (-0.96%)
AMD   83.42 (+1.74%)
T   28.58 (+0.25%)
F   6.74 (+1.20%)
ACB   4.70 (+1.08%)
GILD   62.86 (-0.52%)
NFLX   506.04 (+1.20%)
DIS   124.20 (+0.10%)
BA   170.08 (+2.92%)
BAC   24.10 (+0.04%)
S&P 500   3,384.40 (+0.64%)
DOW   27,906.44 (+0.45%)
QQQ   280.85 (+1.08%)
AAPL   116.62 (+0.70%)
MSFT   212.16 (+0.87%)
FB   266.04 (+1.58%)
GOOGL   1,485.87 (+1.38%)
AMZN   3,189.69 (+1.30%)
TSLA   438.98 (+2.32%)
NVDA   541.52 (+0.06%)
BABA   291.17 (-0.96%)
CGC   14.23 (-0.63%)
MU   47.56 (+1.28%)
GE   6.17 (-0.96%)
AMD   83.42 (+1.74%)
T   28.58 (+0.25%)
F   6.74 (+1.20%)
ACB   4.70 (+1.08%)
GILD   62.86 (-0.52%)
NFLX   506.04 (+1.20%)
DIS   124.20 (+0.10%)
BA   170.08 (+2.92%)
BAC   24.10 (+0.04%)
S&P 500   3,384.40 (+0.64%)
DOW   27,906.44 (+0.45%)
QQQ   280.85 (+1.08%)
AAPL   116.62 (+0.70%)
MSFT   212.16 (+0.87%)
FB   266.04 (+1.58%)
GOOGL   1,485.87 (+1.38%)
AMZN   3,189.69 (+1.30%)
TSLA   438.98 (+2.32%)
NVDA   541.52 (+0.06%)
BABA   291.17 (-0.96%)
CGC   14.23 (-0.63%)
MU   47.56 (+1.28%)
GE   6.17 (-0.96%)
AMD   83.42 (+1.74%)
T   28.58 (+0.25%)
F   6.74 (+1.20%)
ACB   4.70 (+1.08%)
GILD   62.86 (-0.52%)
NFLX   506.04 (+1.20%)
DIS   124.20 (+0.10%)
BA   170.08 (+2.92%)
BAC   24.10 (+0.04%)
S&P 500   3,384.40 (+0.64%)
DOW   27,906.44 (+0.45%)
QQQ   280.85 (+1.08%)
AAPL   116.62 (+0.70%)
MSFT   212.16 (+0.87%)
FB   266.04 (+1.58%)
GOOGL   1,485.87 (+1.38%)
AMZN   3,189.69 (+1.30%)
TSLA   438.98 (+2.32%)
NVDA   541.52 (+0.06%)
BABA   291.17 (-0.96%)
CGC   14.23 (-0.63%)
MU   47.56 (+1.28%)
GE   6.17 (-0.96%)
AMD   83.42 (+1.74%)
T   28.58 (+0.25%)
F   6.74 (+1.20%)
ACB   4.70 (+1.08%)
GILD   62.86 (-0.52%)
NFLX   506.04 (+1.20%)
DIS   124.20 (+0.10%)
BA   170.08 (+2.92%)
BAC   24.10 (+0.04%)
Log in
NASDAQ:AIMT

Aimmune Therapeutics Stock Forecast, Price & News

$34.43
-0.02 (-0.06 %)
(As of 10/1/2020 11:23 AM ET)
Add
Compare
Today's Range
$34.41
Now: $34.43
$34.44
50-Day Range
$11.99
MA: $25.81
$34.35
52-Week Range
$10.09
Now: $34.43
$37.00
Volume19,513 shs
Average Volume1.72 million shs
Market Capitalization$2.25 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.71
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Read More
Aimmune Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AIMT
CUSIPN/A
Phone650-614-5220

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.66 per share

Profitability

Net Income$-248,500,000.00

Miscellaneous

Employees228
Market Cap$2.25 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$34.43
-0.02 (-0.06 %)
(As of 10/1/2020 11:23 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AIMT News and Ratings via Email

Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions

How has Aimmune Therapeutics' stock been impacted by COVID-19?

Aimmune Therapeutics' stock was trading at $17.57 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AIMT shares have increased by 96.0% and is now trading at $34.43.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aimmune Therapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Aimmune Therapeutics
.

When is Aimmune Therapeutics' next earnings date?

Aimmune Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Aimmune Therapeutics
.

How were Aimmune Therapeutics' earnings last quarter?

Aimmune Therapeutics Inc (NASDAQ:AIMT) posted its quarterly earnings data on Thursday, July, 30th. The biotechnology company reported ($1.06) EPS for the quarter, hitting the Zacks' consensus estimate of ($1.06).
View Aimmune Therapeutics' earnings history
.

What price target have analysts set for AIMT?

11 analysts have issued twelve-month price targets for Aimmune Therapeutics' stock. Their forecasts range from $15.00 to $60.00. On average, they anticipate Aimmune Therapeutics' stock price to reach $37.13 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price.
View analysts' price targets for Aimmune Therapeutics
.

Are investors shorting Aimmune Therapeutics?

Aimmune Therapeutics saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 6,740,000 shares, a drop of 62.2% from the August 31st total of 17,850,000 shares. Based on an average daily volume of 2,080,000 shares, the days-to-cover ratio is currently 3.2 days. Currently, 14.7% of the shares of the stock are sold short.
View Aimmune Therapeutics' Short Interest
.

Who are some of Aimmune Therapeutics' key competitors?

What other stocks do shareholders of Aimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Square (SQ), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Roku (ROKU) and Advanced Micro Devices (AMD).

Who are Aimmune Therapeutics' key executives?

Aimmune Therapeutics' management team includes the following people:
  • Dr. Jayson Donald Alexander Dallas, Pres, CEO & Director (Age 51)
  • Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 59)
  • Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 52)
  • Dr. Stephen George Dilly, Special Advisor (Age 59)
  • Dr. Daniel C. Adelman, Chief Medical Officer (Age 62)

When did Aimmune Therapeutics IPO?

(AIMT) raised $124 million in an IPO on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as the underwriters for the IPO.

What is Aimmune Therapeutics' stock symbol?

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

How do I buy shares of Aimmune Therapeutics?

Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aimmune Therapeutics' stock price today?

One share of AIMT stock can currently be purchased for approximately $34.43.

How big of a company is Aimmune Therapeutics?

Aimmune Therapeutics has a market capitalization of $2.25 billion. The biotechnology company earns $-248,500,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. Aimmune Therapeutics employs 228 workers across the globe.

What is Aimmune Therapeutics' official website?

The official website for Aimmune Therapeutics is www.aimmune.com.

How can I contact Aimmune Therapeutics?

Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected]

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.